Do you expect Copaxone to post as impressive of a growth rate? I suspect it's losing more patients to Gylenia.
Btw, what was the original reasoning for comparing/contrasting Tysabri vs. Copaxone? Why not think of Copaxone within the usual ABCR competitive basket?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.